Malaria is one of the leading causes of death in Nigeria. According to the 2020 World Malaria Report, Nigeria accounts for 27 percent of malaria cases globally and 23 percent of deaths from the disease, 30 percent of admissions to Nigeria’s hospitals are as a result of malaria. In Nigeria, there is still insufficient data around health more widely, which impacts the amount of evidence available for decision-making. We support the National Malaria Elimination Programme to build capacity within the health system more broadly and support in the delivery of malaria interventions in the country.
Malaria Consortium is supporting the Nigerian government and working with partners to undertake a study to assess the clinical effectiveness and operational feasibility of intermittent preventive treatment of malaria in infants (IPTi) in Nigeria. It aims to generate the necessary evidence to support the intervention’s uptake in the national health policy. The project is funded by BMGF and runs from November 2020 to October 2024.
Malaria Consortium will support the following deliverables for the Effect IPTi project: A simulation report and recommendations and potential study outcomes, which includes raw data, a completed assessment tool questionnaire, the creation of a Statistical Analysis Plan, as well as statistical support and the application of a framework.
Malaria Consortium in partnership with PATH, received a grant from the Givewell to accelerate the scale-up of IPTi in Nigeria and the Democratic Republic of Congo (DRC) by building upon learnings from Sierra Leone’s IPTi experience, the only country that has fully rolled out IPTi, as well as other ongoing IPTi projects funded by the Bill & Melinda Gates Foundation, UNITAID, and the Global Fund to Fight AIDS, Tuberculosis and Malaria across Africa.
This study aims to provide additional evidence to support policy makers’ decision-making regarding full integration of VAS with SMC campaigns at scale and in diverse settings in Nigeria. Malaria Consortium is designing and implementing an integrated SMC plus VAS campaign at scale in Bauchi state and will assess the feasibility and acceptability of integration among caregivers, field implementers, and policy makers. The grant is funded by the Bill & Melinda Gates Foundation through The Task Force for Global Health.
Malaria Consortium is providing technical assistance to support Niger state in north-central Nigeria with the implementation of a community-based primary healthcare (PHC) programme that is integrated with the Community Health Influencers, Promoters and Services (CHIPS) programme launched by Nigeria’s National Primary Health Care Development Agency.
The objective of the SMC IMPACT programme is to reduce malaria morbidity and improve geographic coverage with SMC.The two supported LGAs are Ningi and Tafawa Balewa; and in the first year, a total of 265,000 eligible children were covered. The end of round (EoR) survey report indicated a 94.5% coverage of all eligible children in Bauchi State and 98.5% of the covered children receiving full course perventive treatment for at least 3 of the 4 cycles.
Malaria Consortium received grants to implement insecticide-treated net (ITN) distribution campaign in collaboration with the National Malaria Elimination Programme (NMEP) in Ondo and Anambra states through philanthropic funding.The goal of the ITN Campaign is to contribute to the reduction of malaria burden to pre-elimination levels while bringing malaria-related mortality to zero.
Malaria Consortium has been working in Nigeria since 2008, with offices in Niger, Kaduna, Anambra, Katsina, Kano and Jigawa states. Working in partnership with the Ministry of Health and other partners, we lead and support malaria control initiatives in the country, providing technical support for malaria control; capacity building and training of health workers; health systems strengthening; behaviour change communications and community outreach and operational research, policy and advocacy.
Malaria Consortium is supporting Nigeria’s National Malaria Elimination Programme to deliver a set of interventions that are designed to develop capacity around reporting and case management within the public health system. The project will be implemented in 13 highly populous malaria-endemic states, with Malaria Consortium delivering interventions at the health facility level in Jigawa, Kaduna, Kano, Niger and Yobe. We are also implementing the integrated community case management component of the grant in Jigawa and Niger, as part of the Community Health Influencers, Promoters and Services (CHIPS) intervention; distribute long lasting insecticidal nets (LLINs) in Jigawa and Yobe; and deliver seasonal malaria chemoprevention (SMC) in Jigawa, Kaduna, Kano and Niger. This project is funded by the Global Fund to Fight Malaria, Tuberculosis and HIV/AIDS.
Seasonal malaria chemoprevention (SMC) is a highly effective intervention to prevent malaria in those most vulnerable to the disease’s effects. It involves administering up to four monthly doses of antimalarial drugs to children aged 3-59 months during peak malaria transmission season. Through our SMC programme, we work with malaria control programmes to deliver SMC using existing health system mechanisms as much as possible. We assist in the training of volunteer community health workers and distributors to administer SMC (as well as their supervisors and other health staff) and we also conduct social mobilisation, disseminating public health messages to inform communities of SMC and how and why their children should receive it.
Malaria Consortium began with early implementation pilot of SMC in Nigeria in 2013 leading to policy adoption of SMC as malaria control strategy in Nigeria. Malaria Consortium now covers over 14 million eligible children across 12 states in Nigeria. This has stimulated more investment from major donors including the U.S. President's Malaria Initiative (PMI) and the Global Fund with the resultant effect of 100 percent (about 21 million) coverage of eligible children in Nigeria with the SMC intervention.
SuNMaP 2 is a UK aid-funded follow-up to SuNMaP, supporting the government’s efforts to further reduce Nigeria’s malaria burden. The programme integrates malaria prevention, treatment, and other interventions at the community and service delivery levels, as well as in other settings, through public and private sector partnerships. The project aims improve the planning, financing and delivery of sustainable malaria programmes across 165 local government areas in six states of Nigeria: Jigawa, Kaduna, Kano, Katsina, Lagos, and Yobe.